China Pharma Holdings (CPHI) Change in Receivables (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Change in Receivables came in at $14019.0 in Q1 2026, down 91.49% YoY from $164670.0 in Q1 2025, and up 100.1% on a QoQ basis from -$13.5 million in Q4 2025.
China Pharma Holdings (CPHI) Change in Receivables (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Change in Receivables data on file, last reported at $14019.0 in Q1 2026.
- Quarterly Change in Receivables fell 91.49% year-over-year to $14019.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.4 million (down 2867.3% YoY) and the FY2025 annual result came in at -$13.2 million, down 6780.77% from the prior year.
- Change in Receivables climbed to $14019.0 in Q1 2026, from -$13.5 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $434306.0 in Q1 2023 to a low of -$13.5 million in Q4 2025.
- A 5-year average of -$699321.9 and a median of $110025.0 in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables surged 578.17% — and 2025, when it sank 6444.99%.
- Tracing CPHI's Change in Receivables over 5 years: stood at $107286.0 in 2022, then jumped by 239.52% to $364258.0 in 2023, then tumbled by 41.54% to $212942.0 in 2024, then slumped by 6444.99% to -$13.5 million in 2025, then soared by 100.1% to $14019.0 in 2026.
- The last three Change in Receivables figures came in at $14019.0 (Q1 2026), -$13.5 million (Q4 2025), and $117491.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | China Pharma Holdings | 42.13 Mn | 41.82 Mn | 83,566.00 | 151,378.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,019.00 |
| Mar 31, 2026 | 14,019.00 |
| Dec 31, 2025 | -13.51 Mn |
| Dec 31, 2025 | -13.51 Mn |
| Sep 30, 2025 | 117,491.00 |
| Sep 30, 2025 | 117,491.00 |
| Jun 30, 2025 | 20,566.00 |
| Jun 30, 2025 | 20,566.00 |
| Mar 31, 2025 | 164,670.00 |
| Mar 31, 2025 | 164,670.00 |
| Dec 31, 2024 | 212,942.00 |
| Dec 31, 2024 | 212,942.00 |
| Sep 30, 2024 | 167,299.00 |
| Sep 30, 2024 | 167,299.00 |
| Jun 30, 2024 | -62,163.00 |
| Jun 30, 2024 | -62,163.00 |
| Mar 31, 2024 | -120,370.00 |
| Mar 31, 2024 | -120,370.00 |
| Dec 31, 2023 | 364,258.00 |
| Dec 31, 2023 | 364,258.00 |